Pirfenidone gel in patients with localized scleroderma: A phase II study

Arthritis Research and Therapy

Volumn 16, Issue , 2014, Pages

  Rodríguez Castellanos, Marco ^a   Tlacuilo Parra, Alberto ^b   Sánchez Enríquez, Sergio ^c   Vélez Gómez, Ezequiel ^d   Guevara Gutiérrez, Elizabeth ^a  

^a INSTITUTO DERMATOLÓGICO DE JALISCO DR JOSÉ BARBA RUBIO   (Mexico)

^b INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^c UNIVERSITY OF GUADALAJARA   (Mexico)

^d HOSPITAL CIVIL DE GUADALAJARA FRAY ANTONIO ALCALDE   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

PIRFENIDONE; ANALGESIC AGENT; GEL; NONSTEROID ANTIINFLAMMATORY AGENT; PYRIDONE DERIVATIVE; EOSIN; HEMATOXYLIN;

ADULT; APPLICATION SITE BURNING; ARTICLE; CLINICAL ARTICLE; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; GEL; HUMAN; PHASE 2 CLINICAL TRIAL; PRURITUS; SCLERODERMA; SCORING SYSTEM; SKIN INDURATION; TREATMENT DURATION; CLINICAL TRIAL; FEMALE; MALE; MIDDLE AGED; SCLERODERMA, LOCALIZED; TOPICAL DRUG ADMINISTRATION; ABNORMAL LABORATORY RESULT; ADIPOSE TISSUE; AGED; ASSESSMENT OF HUMANS; BURNING SENSATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DERMATITIS; HISTOPATHOLOGY; LOCALIZED SCLERODERMA; MODIFIED LOCALIZED SCLERODERMA SKIN SEVERITY INDEX; PUNCH BIOPSY; SKIN ATROPHY; SKIN FIBROSIS; VISUAL ANALOG SCALE; YOUNG ADULT;

ADMINISTRATION, TOPICAL; ADULT; ANALGESICS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; FEMALE; GELS; HUMANS; MALE; MIDDLE AGED; PYRIDONES; SCLERODERMA, LOCALIZED;

EID: 84924322619     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/s13075-014-0510-4     Document Type: Article

References (24)

1. Leitenberger JJ, Cayce RL, Haley RW, Adams-Huet B, Bergstresser PR, Jacobe HT: Distinct autoimmune syndromes in morphea: a review of 245 adult and pediatric cases. Arch Dermatol 2009, 145:545-550.
2. Badea I, Taylor M, Rosenberg A, Foldvari M: Pathogenesis and therapeutic approaches for improved topical treatment in localized scleroderma and systemic sclerosis. Rheumatology 2009, 48:213-221.
3. Nakazato H, Oku H, Yamane S, Tsuruta Y, Suzuki R: A novel anti-fibrotic agent pirfenidone suppresses tumor necrosis factor-α at the translational level. Eur J Pharmacol 2002, 446:177-185.
4. Iyer SN, Gurujeyalakshmi G, Giri SN: Effects of pirfenidone on transforming growth factor-β gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis. J Pharmacol Exp Ther 1999, 291:367-373.
5. Lee BS, Margolin SB, Nowak RA: Pirfenidone: a novel pharmacological agent that inhibits leiomyoma cell proliferation and collagen production. J Clin Endocrinol Metab 1998, 83:219-223.
6. Cain WC, Stuart RW, Lefkowitz DL, Starnes JD, Margolin S, Lefkowitz SS: Inhibition of tumor necrosis factor and subsequent endotoxin shock by pirfenidone. Int J Immunopharmacol 1998, 20:685-695.
7. Azuma A, Nukiwa T, Tsuboi E, Suga M, Abe S, Nakata K, Taguchi Y, Nagai S, Itoh H, Ohi M, Sato A, Kudoh S: Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2005, 171:1040-1047.
8. Dosanjh A: Pirfenidone: a novel potential therapeutic agent in the management of chronic allograft rejection. Transplant Proc 2007, 39:2153-2156.
9. Arkachaisri T, Vilaiyuk S, Li S, O'Neil KM, Pope E, Higgins GC, Punaro M, Ravinovich EC, Rosenkranz M, Kietz DA, Rosen P, Spalding SJ, Hennon TR, Torok KS, Cassidy E, Medsger TA Jr, Localized Scleroderma Clinical and Ultrasound Study Group: The Localized Scleroderma Skin Severity Index and Physician Global Assessment of Disease Activity: a work in progress toward development of localized scleroderma outcome measures. J Rheumatol 2009, 36:2819-2829.
10. Kroft EB, Groeneveld TJ, Seyger MM, de Jong EM: Efficacy of topical tacrolimus 0.1% in active plaque morphea: randomized, double-blind, emollient-controlled pilot study. Am J Clin Dermatol 2009, 10:181-187.
11. Kissin EY, Schiller AM, Gelbard RB, Anderson JJ, Falanga V, Simms RW, Korn JH, Merkel PA: Durometry for the assessment of skin disease in systemic sclerosis. Arthritis Rheum 2006, 55:603-609.
12. Long CC, Finlay AY: The finger-tip unit-a new practical measure. Clin Exp Dermatol 1991, 16:444-447.
13. Kreuter A, Gambichler T, Breuckmann F, Rotterdam S, Freitag M, Stuecker M, Hoffmann K, Altmeyer P: Pulsed high-dose corticosteroids combined with low-dose methotrexate in severe localized scleroderma. Arch Dermatol 2005, 141:847-852.
14. Fett N, Werth VP: Update on morphea: Part II. Outcome measures and treatment. J Am Acad Dermatol 2011, 64:231-242.
15. Dytoc M, Ting PT, Man J, Sawyer D, Fiorillo L: First case series on the use of imiquimod for morphoea. Br J Dermatol 2005, 153:815-820.
16. Merkel PA, Silliman NP, Denton CP, Furst DE, Khanna D, Emery P, Hsu VM, Streisand JB, Polisson RP, Åkesson A, Coppock J, van den Hoogen F, Herrick A, Mayes MD, Veale D, Seibold JR, Black CM, Korn JH: Validity, reliability, and feasibility of durometer measurements of scleroderma skin disease in a multicenter treatment trial. Arthritis Rheum 2008, 59:699-705.
17. Kreuter A, Hyun J, Stücker M, Sommer A, Altmeyer P, Gambichler T: A randomized controlled study of low-dose UVA1, medium-dose UVA1, and narrowband UVB phototherapy in the treatment of localized scleroderma. J Am Acad Dermatol 2006, 54:440-447.
18. Carter NJ: Pirfenidone: in idiopathic pulmonary fibrosis. Drugs 2011, 71:1721-1732.
19. Macías-Barragán J, Sandoval-Rodríguez A, Navarro-Partida J, Armendáriz-Borunda J: The multifaceted role of pirfenidone and its novel targets. Fibrogenesis Tissue Repair 2010, 3:16.
20. Armendariz-Borunda J, Lyra-Gonzalez I, Medina-Preciado D, Gonzalez-Garcia I, Martinez-Fong D, Miranda RA, Magaña-Castro R, Peña-Santoyo P, Garcia-Rocha S, Bautista CA, Godoy J, Flores-Montana J, Floresvillar-Mosqueda J, Armendariz-Vazquez O, Lucano-Landeros MS, Vazquez-Del Mercado M, Sanchez-Parada MG: A controlled clinical trial with pirfenidone in the treatment of pathological skin scarring caused by burns in pediatric patients. Ann Plast Surg 2012, 68:22-28.
21. Stefanaki C, Stefanaki K, Kontochristopoulos G, Antoniou C, Stratigos A, Nicolaidou E, Gregoriou S, Katsambas A: Topical tacrolimus 0.1% ointment in the treatment of localized scleroderma: an open label clinical and histological study. J Dermatol 2008, 35:712-718.
22. Zwischenberger BA, Jacobe HT: A systematic review of morphea treatments and therapeutic algorithm. J Am Acad Dermatol 2011, 65:925-941.
23. Dytoc MT, Kossintseva I, Ting PT: First case series on the use of calcipotriol-betamethasone dipropionate for morphoea. Br J Dermatol 2007, 157:615-618.
24. Khanna D: Diagnosis and treatment of systemic and localized scleroderma. Exp Rev Dermatol 2011, 6:287-302.